Diageo plc vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Diageo plc trades at $86.72 (market cap $47.67B), while Nuvation Bio Inc. Class A Common Stock trades at $5.03 (market cap $1.74B). The key difference: Diageo plc is far larger — about 27.4× Nuvation Bio Inc. Class A Common Stock's market cap, and Diageo plc pays a 2.3% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Nuvation Bio Inc. Class A Common Stock for 1 Days on average.
| DEO | NUVB | |
|---|---|---|
Market Cap | $47.67B | $1.74B |
Volume | 893,372 | 9,289,619 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $9.54 |
52-Week Low | $72.47 | $3.41 |
Typical Hold Time | 66 Days | 1 Days |
Enterprise Value | $68.09B | $1.33B |
Dividend Yield | 2.3% | — |
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.82, up 2.47% with bullish technical signals and strong analyst support. The stock shows solid fundamentals with consistent earnings beats, a 15.82% ROE, and improving cash flow trends. Recent corporate developments include a new CFO appointment and marketing initiatives supporting brand strength amid ongoing US business restructuring.
The outlook remains positive with 49% analyst buy ratings and cost-saving initiatives driving margin improvement. Key risks include US market volatility and regulatory challenges in India. The stock presents a compelling turnaround story with valuation support at current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →